ResMed (RMD) CFO Aaron Bloomer Receives Award

What Happened

• Aaron Bloomer, Chief Financial Officer of ResMed Inc. (RMD), was credited with 9,072 performance-based restricted stock units (RSUs) on August 14, 2026. The Form 4 shows an acquisition (award) of 9,072 shares at $0.00 (total $0 recorded), reflecting the RSUs vesting/being earned rather than a cash purchase.

Key Details

• Transaction date: August 14, 2026; reported on Form 4 filed October 1, 2026 (late filing).
• Transaction type/code: A — Award/Grant (performance RSUs earned and treated as acquired).
• Shares involved: 9,072 RSUs vested/earned.
• Price/value shown on Form 4: $0.00 per share; total $0 recorded (compensation award converted into shares upon vesting).
• Shares owned after transaction: Not specified in the filing provided.
• Footnote: These were performance-based RSUs granted on June 1, 2026; they were certified as earned on August 14, 2026 when the compensation committee confirmed performance metrics were met. The RSUs vest in three installments (one‑third each year on the grant anniversary).
• Timeliness: Filing appears late (transaction Aug 14, 2026; Form 4 filed Oct 1, 2026). Late Form 4s should be noted by investors as they delay public disclosure of insider activity.

Context

• This was a compensation-related vesting of performance RSUs, not an open-market purchase or sale. Such awards are common as part of executive pay and do not by themselves indicate buying or selling sentiment.
• No tax withholding, share sales, or option exercises were reported in this transaction.